HMI-115 Australian Phase 1 Trial completed? 10/18/2023
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Any news on potential hair loss treatments?
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
Related Research
6 / 6 resultsresearch The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Controlled Trial
In this study, researchers reported that an herbal extract with dihydroquercetin glucoside, epigallocatechin gallate glucoside, zinc, and glycine showed similar effectiveness and safety to minoxidil in treating androgenetic alopecia over 24 weeks, with no significant differences in hair growth outcomes between the groups.
research Ingredients of Trichological Shampoos with Alleged Beneficial Effects on Hair—What Is Really Known About Their Efficacy? A Scoping Review of an Area with More Unknowns than Knowns
This study found that of the many ingredients advertised in shampoos as effective against hair loss, only caffeine, adenosine, placental proteins, and melatonin have limited clinical evidence supporting their efficacy, with most claimed active ingredients lacking any trial-based validation.
research Exhaustive analysis of scalp hair regression: subjective and objective perception from initial hair loss to severe miniaturisation and drug-induced regrowth
This study found that hair mass index can effectively link hair productivity with clinical scalp coverage perception, suggesting its potential usefulness in diagnosing hair loss patterns and responses to treatment.
research Recent approaches of antibody therapeutics in androgenetic alopecia
This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.
research A dietary supplement improves age-related dermatological changes. Observational, anecdotal, spontaneous study.
This study found that dietary supplementation with collagen, chondroitin sulfate, low-molecular weight hyaluronic acid, Pycnogenol®, and coenzyme Q10 significantly improved skin hydration, elasticity, nail hardness, and hair condition in patients with age-related dermatological changes after 12 weeks.